某院45例新型冠状病毒肺炎患者药品不良反应分析

Adverse Drug Reactions in 45 Patients with COVID-19

目的分析我院新型冠状病毒肺炎(COVID-19)患者治疗期间发生的药品不良反应(ADR)。方法临床药师通过问卷星调查、康网系统、查阅病程等方式收集ADR,对其性别、年龄、既往病史、过敏史、报告类型、怀疑药品、用法用量、不良反应临床表现等进行回顾性分析。结果收集ADR共45例,ADR发生率为12.4%,其中一般的44例(已知的39例、新的5例)、严重的1例。ADR发生较多的为抗病毒药物洛匹那韦/利托那韦片(LPV/r)、糖皮质激素甲泼尼龙(MP)、抗菌药物莫西沙星。结论临床使用多种药物治疗COVID-19时应严格掌握用药指征以及患者基本情况、药物相互作用、注意事项等。关注疗效同时对ADR也应积极宣教、及时发现与上报,进一步保障患者安全用药。

Objective To analyze the adverse drug reactions(ADRs)that occurred during the treatment of patients with COVID-19 in our hospital.Methods Cases of ADRs were collected by clinical pharmacists via questionnaire survey,Kan gnet system,and disease course review.The gender,age,previous medical history,allergic history,report type,suspected drugs,usage and dosage,and clinical manifestations of adverse reactions were retrospectively analyzed.Results A total of 45 ADR cases were collected,and the incidence of ADR was 12.4%,including 44 cases in general(39 known cases,5 new cases),and one case of severe ADRs.ADRs occurred more frequently with antiviral drugs lopinavir/ritonavir tablets(LPV/r),glucocorticoid methylprednisolone(MP),and the antibacterial drug moxifloxacin.Conclusion During clinical use of multiple drugs for COVID-19,it is necessary to have a clear idea about indications,patients’health status,drug interactions and precautions.While efficacy is emphasized,related ADRs should also be made better-known,spotted and reported in time to ensure the safety of drug use.